This evaluation for the KFF-Peterson Well being System Tracker compares the Medicare’s first-ever negotiated drug costs beneath a brand new course of created by the Inflation Discount Act of 2022 to present U.S. listing costs, costs negotiated by the Division of Veterans Affairs (VA), and costs in 11 international locations of comparable dimension and wealth.
It finds that Medicare’s negotiated costs for 10 high-expenditure pharmaceuticals are decrease than what personal Medicare drug plans had been paying, however nonetheless a lot greater than the costs obtainable in different international locations – 78% extra on common than the nation with the subsequent highest worth throughout 11 different rich nations.
The evaluation is offered on the Peterson-KFF Well being System Tracker, an internet info hub devoted to monitoring and assessing the efficiency of the U.S. well being system.
